Avidity Biosciences (RNA) Accumulated Depreciation & Amortization: 2019-2025
Historic Accumulated Depreciation & Amortization for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $10.4 million.
- Avidity Biosciences' Accumulated Depreciation & Amortization rose 43.92% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.8 million, marking a year-over-year increase of 47.93%. This contributed to the annual value of $8.0 million for FY2024, which is 53.17% up from last year.
- Avidity Biosciences' Accumulated Depreciation & Amortization amounted to $10.4 million in Q3 2025, which was up 8.87% from $9.6 million recorded in Q2 2025.
- Over the past 5 years, Avidity Biosciences' Accumulated Depreciation & Amortization peaked at $10.4 million during Q3 2025, and registered a low of $1.7 million during Q1 2021.
- Its 3-year average for Accumulated Depreciation & Amortization is $6.7 million, with a median of $6.5 million in 2024.
- In the last 5 years, Avidity Biosciences' Accumulated Depreciation & Amortization declined by 12.43% in 2021 and then surged by 80.03% in 2022.
- Quarterly analysis of 5 years shows Avidity Biosciences' Accumulated Depreciation & Amortization stood at $1.7 million in 2021, then soared by 80.03% to $3.1 million in 2022, then surged by 67.34% to $5.2 million in 2023, then soared by 53.17% to $8.0 million in 2024, then skyrocketed by 43.92% to $10.4 million in 2025.
- Its Accumulated Depreciation & Amortization was $10.4 million in Q3 2025, compared to $9.6 million in Q2 2025 and $8.8 million in Q1 2025.